Literature DB >> 3511804

Studies on the pathogenesis of Salmonella typhimurium and Salmonella choleraesuis var kunzendorf infection in weanling pigs.

W M Reed, H J Olander, H L Thacker.   

Abstract

Twenty-six 4-week-old pigs were randomly allotted to 4 groups: group 1--orally inoculated with Salmonella typhimurium; group 2--orally dosed with S choleraesuis; and groups 3 and 4, with surgically constructed intestinal loops--loops inoculated with either S typhimurium or S choleraesuis. One pig each from groups 1 and 2 was killed at 8, 12, 24, 48, 72, 96, and 120 hours after inoculation. One pig each from groups 3 and 4 was killed at 2, 4, 6, 8, 12, and 24 hours after intestinal loop inoculation. Inoculation of S typhimurium resulted in acute enterocolitis of variable severity, whereas inoculation of S choleraesuis resulted initially in septicemia followed by formation of large necrotic and ulcerative lesions in the colonic mucosa. The most consistent systemic lesion of S choleraesuis infection was interstitial pneumonia and multifocal hepatic necrosis. Salmonella typhimurium and S choleraesuis were ultrastructurally within enterocytes of ligated ileal loops. Intracellular bacteria were morphologically intact, occurred free in the cytoplasm and membrane bound, and caused no detectable cytotoxic effect to the cell. Both S typhimurium and S choleraesuis penetrated the intestinal mucosa and were isolated from mesenteric lymph nodes at 2 hours after inoculation.

Entities:  

Mesh:

Year:  1986        PMID: 3511804

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  21 in total

1.  Attenuation and immunogenicity of Deltacya Deltacrp derivatives of Salmonella choleraesuis in pigs.

Authors:  M J Kennedy; R J Yancey; M S Sanchez; R A Rzepkowski; S M Kelly; R Curtiss
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

2.  Novel attenuated Salmonella enterica serovar Choleraesuis strains as live vaccine candidates generated by signature-tagged mutagenesis.

Authors:  Yu-We Ku; Sean P McDonough; Raghavan U M Palaniappan; Chao-Fu Chang; Yung-Fu Chang
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

3.  Assessment of various treatments to reduce carriage of Salmonella in swine.

Authors:  A Letellier; S Messier; L Lessard; S Quessy
Journal:  Can J Vet Res       Date:  2000-01       Impact factor: 1.310

Review 4.  Animal Models for Salmonellosis: Applications in Vaccine Research.

Authors:  Ellen E Higginson; Raphael Simon; Sharon M Tennant
Journal:  Clin Vaccine Immunol       Date:  2016-09-06

5.  Host response to various treatments to reduce Salmonella infections in swine.

Authors:  A Letellier; S Messier; L Lessard; S Chénier; S Quessy
Journal:  Can J Vet Res       Date:  2001-07       Impact factor: 1.310

Review 6.  Salmonella enterica serotype Choleraesuis: epidemiology, pathogenesis, clinical disease, and treatment.

Authors:  Cheng-Hsun Chiu; Lin-Hui Su; Chishih Chu
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

7.  Quantitative analysis and partial characterization of cytotoxin production by Salmonella strains.

Authors:  S Ashkenazi; T G Cleary; B E Murray; A Wanger; L K Pickering
Journal:  Infect Immun       Date:  1988-12       Impact factor: 3.441

8.  Swine immunity to an attenuated Salmonella typhimurium mutant containing a recombinant plasmid which codes for production of a 31-kilodalton protein of Brucella abortus.

Authors:  T J Stabel; J E Mayfield; L B Tabatabai; M J Wannemuehler
Journal:  Infect Immun       Date:  1991-09       Impact factor: 3.441

9.  Immune response of pigs to parenteral vaccination with an aromatic-dependent mutant of Salmonella typhimurium.

Authors:  J S Lumsden; B N Wilkie
Journal:  Can J Vet Res       Date:  1992-10       Impact factor: 1.310

10.  Natural transmission of Salmonella choleraesuis in swine.

Authors:  J T Gray; P J Fedorka-Cray; T J Stabel; T T Kramer
Journal:  Appl Environ Microbiol       Date:  1996-01       Impact factor: 4.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.